Generics and Bioequivalence Knowledge Base Generics and Bioequivalence As the debate about health care in the United States continues forward, the term “generic…CertaraJanuary 10, 2011
What are Compartmental Models? Knowledge Base What are Compartmental Models? Learn about compartmental models and their importance in pharmacokinetics. Find out how they simplify drug…CertaraJanuary 5, 2011
What are Drug-drug Interactions Anyway? Knowledge Base What are Drug-drug Interactions Anyway? A current buzz phrase in pharmaceutical research right now is “drug-drug interaction” or simply “drug…CertaraJanuary 5, 2011
The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain Publication The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain ATP-binding cassette transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) have been shown to…CertaraJanuary 1, 2011
Absorption Rate Knowledge Base Absorption Rate The rate at which a drug enters the body after administration is called the absorption…CertaraDecember 30, 2010
What is a Half-life? Knowledge Base What is a Half-life? One of the most incorrectly used but most often quoted parameters is half life. The…CertaraDecember 20, 2010
Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales Publication Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales This article demonstrates techniques for describing and predicting disease progression in acute stroke by modeling…CertaraDecember 1, 2010
Development of a Modeling Framework to Simulate Efficacy Endpoints for Motesanib in Thyroid Cancer Patients Publication Development of a Modeling Framework to Simulate Efficacy Endpoints for Motesanib in Thyroid Cancer Patients To develop a modeling framework that simulates clinical endpoints (objective response rate and progression-free survival)…CertaraNovember 1, 2010
Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients Publication Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients To develop a population pharmacokinetic/pharmacodynamic model describing the relationship between motesanib exposure and tumor response…CertaraNovember 1, 2010
A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551 Publication A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551 Pharmacokinetic-pharmacodynamic relationships are crucial in understanding a drug's arrhythmogenic potential. Models assist to quantitatively relate…CertaraAugust 21, 2010